Year-end report January-December 2023 CombiGene AB (Publ)

October – December 2023
• Net sales: TSEK 596 (5,346).
• Other operating revenues: TSEK 875 (579).
• Profit from financial items: TSEK -6,360 (-11,942).
• Earnings per share: SEK -0.32 (-0.60).

January – December 2023
• Net sales: TSEK 5,544 (26,699).
• Other operating revenues: TSEK 1,464 (14,548).
• Profit from financial items: TSEK -35,665 (-6,157).
• Earnings per share: SEK -1.80 (-0.31).
• Cash and cash equivalents: TSEK 101,440 (131,777).

Events during quarter 4
• Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene.
• CombiGene and Zyneyro choose initial indication in the COZY01 pain project.
• CombiGene chooses Charles River as preclinical toxicology partner for COZY01 pain project.
• Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project.

Events after the end of the year
• CombiGene regains the global rights to the epilepsy project CG01.
• CombiGene discontinues the preclinical development of the lipodystrophy project CGT2.

Contacts

---

CombiGene AB (publ)
Peter Ekolind, CEO
Phone: [phone]
[e-mail]

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
[phone] [e-mail]

About CombiGene

---

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Please read Ingeneious, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com

Attachments

---

CombiGene Q4 2023 EN

© Modular Finance, source Nordic Press Releases